Clinical Trials - DVAX

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT07207408Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of AgeRECRUITINGPHASE22025-09-112026-10-162026-05-29
NCT06569823Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy AdultsRECRUITINGPHASE1, PHASE22024-06-172026-092026-09
NCT05506969Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of AgeCOMPLETEDPHASE22022-08-092024-04-262023-10-03
NCT05245838Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult VolunteersCOMPLETEDPHASE12022-01-102022-10-202022-10-20
NCT03934736HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing HemodialysisCOMPLETEDPHASE12019-04-222021-09-152020-10-23
NCT03326752Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLCCOMPLETEDPHASE12017-09-202019-09-192019-09-19
NCT02521870A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTERMINATEDPHASE1, PHASE22015-092020-042020-04
NCT02266147Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell LymphomaTERMINATEDPHASE1, PHASE22014-102017-042017-04
NCT02117934Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® VaccineCOMPLETEDPHASE32014-042015-102015-10
NCT01999699A Study of the Immune Response to Heplisav in Healthy Older AdultsCOMPLETEDPHASE12013-112015-032015-02
NCT01195246Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on HemodialysisCOMPLETEDPHASE32010-122012-082012-02
NCT01005407Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B VaccineCOMPLETEDPHASE32010-022011-052011-01
NCT00985426Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) PatientsCOMPLETEDPHASE32009-092012-012012-01
NCT01023230A Study to Assess DV-601 in Subjects With Chronic Hepatitis BCOMPLETEDPHASE12009-092011-052011-05
NCT00823862Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) InfectionCOMPLETEDPHASE12008-102010-022009-12
NCT00599001Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal MalesCOMPLETEDPHASE12008-012008-032008-03
NCT00537355An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure ChamberCOMPLETEDPHASE22007-092008-052008-03
NCT00498212A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal DiseaseTERMINATEDPHASE22007-072008-102008-08
NCT00511095Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus VaccineCOMPLETEDPHASE22007-062008-032007-10
NCT00435812Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® VaccineCOMPLETEDPHASE32006-122008-032008-02
NCT00403052A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal CancerTERMINATEDPHASE12006-112007-122007-12
NCT00387738Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic AdultsTERMINATEDPHASE22006-042008-032007-05
NCT00426712Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure PatientsCOMPLETEDPHASE12006-012008-032008-03